Literature DB >> 26687448

Effects of C-reactive protein on bone cells.

In-Jin Cho1, Kyoung Hee Choi1, Chi Hyuk Oh1, You Cheol Hwang1, In-Kyung Jeong1, Kyu Jeung Ahn1, Ho-Yeon Chung2.   

Abstract

AIMS: Inflammatory processes are involved in bone remodeling. C-reactive protein (CRP) is an acute phase reactant that reflects different degrees of inflammation. Accumulating evidence suggests that CRP is an inflammatory marker and a direct cause of disease. Therefore, we examined the direct effects of CRP on bone cells. MAIN
METHODS: We used RAW 264.7 cells to evaluate the direct effects of CRP on osteoclast differentiation. We carried out alkaline phosphatase (ALP) and bone nodule formation assays using MC3T3-E1 cells to evaluate osteoblast differentiation. Expression of osteoclast-specific and osteoblast-specific genes and effects on cell signaling pathways associated with cell differentiation were analyzed by reverse transcription polymerase chain reaction and Western blotting. KEY
FINDINGS: CRP significantly and dose-dependently inhibited TRAP-positive multinucleated cell formation in RANKL-induced RAW 264.7 cell cultures. We observed suppression of p38, ERK and AKT mitogen-activated protein kinases induced by RANKL in Western blots after CRP treatment of RAW 264.7 cells. CRP also suppressed ALP activity and mineralization by Alizarin red S staining of MC3T3-E1 cell cultures. CRP suppressed osteoclast-specific and osteoblast-specific genes. Furthermore, CRP increased interferon beta (IFN-β) mRNA expression and protein levels in RAW 264.7 and MC3T3-E1 cells, and these effects were suppressed by oxPAPC, an inhibitor of Toll-like receptor (TLR) signaling. SIGNIFICANCE: These data indicated that CRP may have a direct role on osteoclast and osteoblast differentiation via TLR signaling pathways.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  C-reactive protein; Osteoblast; Osteoclast; Toll-like receptor

Mesh:

Substances:

Year:  2015        PMID: 26687448     DOI: 10.1016/j.lfs.2015.12.021

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  10 in total

Review 1.  Alkaline phosphatase: a novel treatment target for cardiovascular disease in CKD.

Authors:  Mathias Haarhaus; Vincent Brandenburg; Kamyar Kalantar-Zadeh; Peter Stenvinkel; Per Magnusson
Journal:  Nat Rev Nephrol       Date:  2017-05-15       Impact factor: 28.314

2.  Assessing the roles of demographic, social, economic, environmental, health-related, and political factors on risk of osteoporosis diagnosis among older adults.

Authors:  Margaret Gough Courtney; Yadira Quintero; K Godde
Journal:  Arch Osteoporos       Date:  2021-11-24       Impact factor: 2.617

Review 3.  Alkaline Phosphatase: An Old Friend as Treatment Target for Cardiovascular and Mineral Bone Disorders in Chronic Kidney Disease.

Authors:  Mathias Haarhaus; Giuseppe Cianciolo; Simona Barbuto; Gaetano La Manna; Lorenzo Gasperoni; Giovanni Tripepi; Mario Plebani; Maria Fusaro; Per Magnusson
Journal:  Nutrients       Date:  2022-05-19       Impact factor: 6.706

4.  Alteration of serum immunoglobins, C-reactive protein, vitamin D, and electrolyte by atenolol and amlodipine in stress-induced hypertensive rats.

Authors:  Moayad Mustafa Hejazi; Ala Osman Bacha; Mohammed Kaleemuddin; Fahad A Al-Abassi; Abdulbasit I Al-Alsieni; Imran Kazmi; Firoz Anwar
Journal:  Mol Cell Biochem       Date:  2017-12-16       Impact factor: 3.396

5.  C-reactive protein (CRP) but not the related pentraxins serum amyloid P and PTX3 inhibits the proliferation and induces apoptosis of the leukemia cell line Mono Mac 6.

Authors:  Wensheng Chen; Darrell Pilling; Richard H Gomer
Journal:  BMC Immunol       Date:  2017-12-04       Impact factor: 3.615

6.  Inflammation and bone mineral density: A Mendelian randomization study.

Authors:  Jian V Huang; C Mary Schooling
Journal:  Sci Rep       Date:  2017-08-17       Impact factor: 4.379

7.  Monomeric C-Reactive Protein Binds and Neutralizes Receptor Activator of NF-κB Ligand-Induced Osteoclast Differentiation.

Authors:  Zhe-Kun Jia; Hai-Yun Li; Yu-Lin Liang; Lawrence Albert Potempa; Shang-Rong Ji; Yi Wu
Journal:  Front Immunol       Date:  2018-02-19       Impact factor: 7.561

8.  HIF1α inhibition facilitates Leflunomide-AHR-CRP signaling to attenuate bone erosion in CRP-aberrant rheumatoid arthritis.

Authors:  Chao Liang; Jie Li; Cheng Lu; Duoli Xie; Jin Liu; Chuanxin Zhong; Xiaohao Wu; Rongchen Dai; Huarui Zhang; Daogang Guan; Baosheng Guo; Bing He; Fangfei Li; Xiaojuan He; Wandong Zhang; Bao-Ting Zhang; Ge Zhang; Aiping Lu
Journal:  Nat Commun       Date:  2019-10-08       Impact factor: 14.919

Review 9.  Pharmacologic epigenetic modulators of alkaline phosphatase in chronic kidney disease.

Authors:  Mathias Haarhaus; Dean Gilham; Ewelina Kulikowski; Per Magnusson; Kamyar Kalantar-Zadeh
Journal:  Curr Opin Nephrol Hypertens       Date:  2020-01       Impact factor: 3.416

Review 10.  Adipose Tissue Dysfunction: Impact on Bone and Osseointegration.

Authors:  Shalinie King; Iven Klineberg; Tara C Brennan-Speranza
Journal:  Calcif Tissue Int       Date:  2021-08-10       Impact factor: 4.333

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.